Astrazeneca Pharma India, 506820, ASTRAZEN Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

22,710.75
123.86
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

22,174.05
0.35%
27.73

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

11.78
16.10
19.61

EBITDA CAGR (%)

10 Years
5 Years
3 Years

31.50
13.39
8.99

PAT CAGR (%)

10 Years
5 Years
3 Years

36.22
4.40
5.24

P:E (Median)

8 Years
5 Years
3 Years

108.28
107.86
99.06

P:BV (Average)

8 Years
5 Years
3 Years

20.37
20.32
21.09

EV:EBITDA (Average)

8 Years
5 Years
3 Years

62.28
65.51
64.59

Earnings Forecasts:

(Updated: 06-06-2025)

Description 2024 2025 2026 2027
Adj EPS 64.6
P/E Ratio 140.79
Revenue 1296
EBITDA 184
Net Income 162
ROA 15.7
P/B Ratio 31.94
ROE 24.84
FCFF 49
FCFF Yield 0.25
Net Debt -501
BVPS 284.77

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 526.31 387.52 35.81% 480.48 383.20 25.39% 440.29 305.79 43.98% 408.00 311.07 31.16%
Expenses 445.20 349.45 27.40% 394.11 333.81 18.06% 363.30 290.74 24.96% 355.46 258.31 37.61%
EBITDA 81.11 38.07 113.05% 86.37 49.39 74.87% 76.99 15.05 411.56% 52.54 52.76 -0.42%
EBIDTM 15.41% 9.82% 17.98% 12.89% 17.49% 4.92% 12.88% 16.96%
Other Income 11.24 8.35 34.61% 16.15 8.66 86.49% 7.98 9.66 -17.39% 8.15 8.37 -2.63%
Interest 0.72 0.11 554.55% 0.68 -0.07 - 0.33 0.61 -45.90% 0.34 0.50 -32.00%
Depreciation 16.57 3.91 323.79% 17.69 3.76 370.48% 9.07 3.70 145.14% 9.32 3.68 153.26%
PBT 74.70 -15.16 - 78.47 54.36 44.35% 42.02 20.40 105.98% 51.03 73.38 -30.46%
Tax 18.87 -3.37 - 20.22 14.88 35.89% 11.17 4.60 142.83% 12.60 21.01 -40.03%
PAT 55.83 -11.79 - 58.25 39.48 47.54% 30.85 15.80 95.25% 38.43 52.37 -26.62%
PATM 10.61% -3.04% 12.12% 10.30% 7.01% 5.17% 9.42% 16.84%
EPS 22.33 -4.72 - 23.30 15.79 47.56% 12.34 6.32 95.25% 15.37 20.95 -26.63%

Description Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 1,855.08 1,716.29 1,295.53 1,002.97 805.60 813.56 831.81 728.29 571.00 543.71 563.73 Net Sales Growth 33.69% 32.48% 29.17% 24.50% -0.98% -2.19% 14.21% 27.55% 5.02% -3.55% Cost Of Goods Sold 1,027.98 957.79 590.03 355.22 305.28 287.30 299.97 226.73 178.21 171.18 194.81 Gross Profit 827.10 758.50 705.50 647.75 500.32 526.26 531.84 501.56 392.79 372.53 368.93 GP Margin 44.59% 44.19% 54.46% 64.58% 62.11% 64.69% 63.94% 68.87% 68.79% 68.52% 65.44% Total Expenditure 1,558.07 1,462.32 1,111.08 837.85 719.42 678.09 711.11 656.99 524.71 506.77 547.31 Power & Fuel Cost - 5.30 4.87 5.54 8.10 7.37 7.72 8.27 8.30 7.68 7.43 % Of Sales - 0.31% 0.38% 0.55% 1.01% 0.91% 0.93% 1.14% 1.45% 1.41% 1.32% Employee Cost - 257.44 241.45 259.10 230.21 219.54 216.70 197.40 150.39 162.04 169.35 % Of Sales - 15.00% 18.64% 25.83% 28.58% 26.99% 26.05% 27.10% 26.34% 29.80% 30.04% Manufacturing Exp. - 48.57 89.46 76.04 57.12 49.32 40.81 49.58 50.67 36.40 25.82 % Of Sales - 2.83% 6.91% 7.58% 7.09% 6.06% 4.91% 6.81% 8.87% 6.69% 4.58% General & Admin Exp. - 75.41 66.30 56.66 40.04 40.69 65.54 74.09 46.49 55.04 59.10 % Of Sales - 4.39% 5.12% 5.65% 4.97% 5.00% 7.88% 10.17% 8.14% 10.12% 10.48% Selling & Distn. Exp. - 103.93 97.48 71.57 62.09 55.94 65.13 88.18 81.07 62.56 84.65 % Of Sales - 6.06% 7.52% 7.14% 7.71% 6.88% 7.83% 12.11% 14.20% 11.51% 15.02% Miscellaneous Exp. - 13.88 21.49 13.72 16.58 17.93 15.24 12.74 9.58 11.87 84.65 % Of Sales - 0.81% 1.66% 1.37% 2.06% 2.20% 1.83% 1.75% 1.68% 2.18% 1.09% EBITDA 297.01 253.97 184.45 165.12 86.18 135.47 120.70 71.30 46.29 36.94 16.42 EBITDA Margin 16.01% 14.80% 14.24% 16.46% 10.70% 16.65% 14.51% 9.79% 8.11% 6.79% 2.91% Other Income 43.52 40.63 34.80 26.10 14.76 12.84 12.99 16.29 12.25 14.39 6.77 Interest 2.07 1.46 1.20 0.63 0.95 1.09 1.14 0.00 0.00 0.00 0.00 Depreciation 52.65 39.99 14.94 16.26 16.95 20.13 18.58 14.92 14.74 15.83 17.43 PBT 246.22 253.15 203.11 174.33 83.04 127.09 113.97 72.67 43.80 35.50 5.76 Tax 62.86 40.62 58.03 34.81 21.44 33.79 41.76 18.22 17.89 15.45 0.50 Tax Rate 25.53% 25.98% 26.43% 25.96% 25.82% 26.59% 36.64% 25.07% 40.84% 43.52% 8.68% PAT 183.36 115.74 161.51 99.29 61.60 93.30 72.21 54.45 25.91 20.05 5.26 PAT before Minority Interest 183.36 115.74 161.51 99.29 61.60 93.30 72.21 54.45 25.91 20.05 5.26 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 9.88% 6.74% 12.47% 9.90% 7.65% 11.47% 8.68% 7.48% 4.54% 3.69% 0.93% PAT Growth 91.28% -28.34% 62.66% 61.19% -33.98% 29.21% 32.62% 110.15% 29.23% 281.18% EPS 73.34 46.30 64.60 39.72 24.64 37.32 28.88 21.78 10.36 8.02 2.10

Results Balance Sheet

Standalone Figures in Rs. Crores

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 770.35 711.92 588.69 511.39 456.17 364.44 300.80 246.93 222.87 156.01 Share Capital 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 Total Reserves 758.20 703.63 581.12 504.44 449.58 357.85 293.70 239.85 216.22 151.01 Non-Current Liabilities 159.13 97.83 68.99 73.63 44.60 44.13 22.75 109.73 88.68 38.96 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 162.24 116.30 85.97 84.91 50.50 49.47 46.11 142.28 128.90 37.70 Current Liabilities 908.15 467.15 484.40 392.30 373.43 367.10 267.60 218.67 202.05 234.05 Trade Payables 456.30 196.51 227.88 190.44 178.37 209.72 168.20 127.20 87.66 94.63 Other Current Liabilities 129.53 110.53 111.95 94.23 82.58 71.06 54.38 39.41 69.84 121.08 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Short Term Provisions 322.32 160.11 144.57 107.63 112.48 86.32 45.02 52.06 44.55 18.33 Total Liabilities 1,837.63 1,276.90 1,142.08 977.32 874.20 775.67 591.15 575.33 513.60 429.02 Net Block 64.24 66.68 68.86 74.49 80.96 71.53 74.83 75.46 86.84 97.36 Gross Block 217.62 187.13 179.12 168.83 159.78 132.84 119.83 105.85 102.57 203.76 Accumulated Depreciation 153.38 120.45 110.26 94.34 78.82 61.31 45.00 30.39 15.73 106.40 Non Current Assets 290.13 234.16 206.14 212.00 185.51 193.49 177.81 242.69 250.34 161.95 Capital Work in Progress 0.00 0.27 1.33 2.20 4.02 24.24 6.90 3.57 4.81 6.31 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 222.24 167.21 135.95 135.31 100.52 97.71 95.83 163.39 158.27 57.68 Other Non Current Assets 3.65 0.00 0.00 0.00 0.01 0.01 0.25 0.27 0.42 0.61 Current Assets 1,547.50 1,042.74 935.94 765.32 688.69 582.18 413.34 332.64 263.26 267.07 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 548.50 227.88 190.21 140.22 159.80 165.15 118.10 113.15 57.71 76.73 Sundry Debtors 184.88 153.13 107.52 85.89 85.19 83.21 79.75 54.63 43.00 83.14 Cash & Bank 536.70 505.84 500.48 448.46 352.35 252.52 173.30 125.92 115.58 76.83 Other Current Assets 277.42 13.23 13.56 12.64 91.35 81.30 42.19 38.94 46.97 30.37 Short Term Loans & Adv. 261.22 142.66 124.17 78.11 77.30 61.45 29.25 30.87 23.43 20.22 Net Current Assets 639.35 575.59 451.54 373.02 315.26 215.08 145.74 113.97 61.21 33.03 Total Assets 1,837.63 1,276.90 1,142.08 977.32 874.20 775.67 591.15 575.33 513.60 429.02

Cash Flow

Standalone Figures in Rs. Crores

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 65.36 27.87 58.29 100.80 104.78 87.42 54.98 8.79 38.10 56.99 PBT 156.36 219.54 134.10 83.04 127.09 113.97 72.67 43.80 35.50 5.76 Adjustment 76.41 -7.07 -4.80 9.66 14.20 9.75 7.62 3.39 14.61 12.11 Changes in Working Capital -103.22 -128.17 -30.19 32.89 -3.95 -2.66 9.81 -34.25 -0.24 42.09 Cash after chg. in Working capital 129.55 84.30 99.11 125.59 137.34 121.06 90.10 12.94 49.87 59.97 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -64.19 -56.43 -40.82 -24.79 -32.56 -33.64 -35.12 -4.15 -11.77 -2.98 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 30.80 21.74 18.11 4.74 173.03 -170.80 4.28 -9.36 0.25 -3.61 Net Fixed Assets -30.22 -6.95 -9.42 -7.23 -6.72 -30.35 -17.31 -2.04 102.69 -6.42 Net Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Others 61.02 28.69 27.53 11.97 179.75 -140.45 21.59 -7.32 -102.44 2.81 Cash from Financing Activity -65.59 -44.38 -24.48 -9.46 -8.97 -6.36 0.00 0.00 0.00 -0.51 Net Cash Inflow / Outflow 30.57 5.23 51.92 96.08 268.84 -89.74 59.26 -0.57 38.35 52.87 Opening Cash & Equivalents 505.57 500.34 448.42 352.34 83.50 173.24 113.98 114.55 76.20 23.33 Closing Cash & Equivalent 536.14 505.57 500.34 448.42 352.34 83.50 173.24 113.98 114.55 76.20

Financial Ratios

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 305.28 283.45 234.45 203.78 181.83 145.14 119.48 97.94 88.49 62.41 ROA 7.43% 13.35% 9.37% 6.65% 11.31% 10.57% 9.34% 4.76% 4.25% 1.25% ROE 15.73% 24.95% 18.13% 12.78% 22.83% 21.83% 20.03% 11.12% 10.63% 3.43% ROCE 21.29% 33.94% 24.49% 17.36% 31.24% 34.61% 26.53% 18.65% 18.74% 3.76% Fixed Asset Turnover 8.51 7.11 5.79 4.93 5.58 6.58 6.45 5.49 3.58 2.88 Receivable days 35.81 36.53 35.03 38.57 37.62 35.75 33.67 31.15 41.96 40.32 Inventory Days 82.25 58.60 59.85 67.64 72.59 62.15 57.95 54.51 44.72 52.15 Payable days 124.39 131.27 214.92 220.48 246.52 99.66 91.40 73.21 75.53 75.14 Cash Conversion Cycle -6.33 -36.14 -120.04 -114.26 -136.32 -1.76 0.22 12.45 11.15 17.33 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Interest Cover 108.10 183.95 213.86 88.41 117.60 100.97 0.00 0.00 0.00 0.00

Top Investors:

nippon life india trustee ltd-a/c nippon india small cap fund(various schemes)

tejas bhalchandra trivedi

shivani tejas trivedi

prashant jain

investor education and protection fund (iepf)

Annual Reports:

News Update:

Astrazeneca Pharma I - Quarterly Results
14th Aug 2025, 14:09 PM

Read More
AstraZeneca Pharma India to launch Eculizumab (Soliris)
7th Aug 2025, 15:57 PM

Eculizumab (Soliris) is indicated for the treatment of patients with PNH and aHUS to inhibit complement
Read More
AstraZeneca Pharma India gets nod to market Durvalumab Solution
15th Jul 2025, 10:12 AM

The company has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India
Read More
AstraZeneca Pharma gets permission to import for sale and distribution of Benralizumab
30th May 2025, 10:00 AM

Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis
Read More
Astrazeneca Pharma India receives approval to import for sale and distribution of Osimertinib Tablets
29th May 2025, 12:50 PM

The company has received permission from the CDSCO to import for sale and distribution of Osimertinib Tablets 40 mg & 80 mg (TAGRISSO) for an additional indication
Read More

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update:

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update: